Cost of treating metastatic colorectal cancer: a systematic review

Bhimani, Nazim; Wong, Geoffrey Yuet Mun; Molloy, Charles; Pavlakis, Nick; Diakos, Connie I.; Clarke, S.J.; Dieng, Mbathio; Hugh, Thomas J.

doi:10.1016/j.puhe.2022.06.022

Cited by 15 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 12 , 13 ] From the perspective of cost accounting results, China’s cancer treatment costs are mainly consumed by lung cancer, breast cancer, stomach cancer, liver cancer, etc., and the health output effect of resource input is poor. [ 14 ] Fourth, the institutional flow direction of costs reflects that the role of grassroots in China’s cancer prevention and treatment system is insufficient. The responsibility orientation of primary medical and health institutions is to provide rehabilitation and nursing services for patients with clear diagnosis during stable period and recovery period.…”

Section: Discussionmentioning

confidence: 99%

Analysis of the composition and influencing factors of hospitalization expenses for 1517 patients with lung malignant tumors in Beijing

Zhao,

Tang

2024

Medicine

View full text Add to dashboard Cite

This study aimed to analyze the composition of the total hospitalization expenses of patients with lung cancer in Beijing TongRen Hospital from January 2018 to December 2020 before and after the implementation of the “Beijing Medical Consumption Linkage Comprehensive Reform Implementation Plan” (hereinafter referred to as “Reform”). The SPSS 25.0 statistical software was used to perform descriptive statistics on the total hospitalization costs of selected 1517 patients with lung malignant tumors, and single factor and multivariate regression analysis were used to clarify the influencing factors of the patients’ total hospitalization costs. From 2018 to 2020, the total hospitalization costs of patients with lung malignant tumors increased year by year (P < .05), and the average length of hospital stay decreased year by year (P < .05). The total hospitalization expenses of patients with lung malignant tumors mainly include material expenses, surgical expenses, inspection expenses, inspection expenses and medicine expenses. After the implementation of the “Reform,” the proportion of medicine, inspection, nursing and other expenses in the total hospitalization expenses of patients with lung malignant tumors has been significantly reduced (P < .05), and the proportion of surgical expenses has been significantly increased (P < .05). The results of the univariate analysis showed that gender, age, length of stay in the hospital, surgery, and tumor location were the main factors affecting the total hospitalization expenses of patients (P < .05). The results of multivariate analysis showed that gender (female), age (<40 years old), length of stay (≥15 days), surgery (yes), and tumor location (right lung) are the main factors affecting the total hospitalization cost of patients with malignant tumors (P < .05). Under the premise of ensuring the efficacy of patients, the economic burden of patients is reduced by reducing the cost of materials, shortening the length of hospitalization, strengthening hospital management, and controlling the continuous growth of hospitalization costs.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of the composition and influencing factors of hospitalization expenses for 1517 patients with lung malignant tumors in Beijing

Zhao,

Tang

2024

Medicine

View full text Add to dashboard Cite

show abstract

“…9 It follows that early diagnosis may also decrease downstream complications, improve outcomes, and minimize costs to the patient and the health care system. 11 Further, early diagnosis helps reduce racial and ethnic disparities in outcomes: when CRC is diagnosed at a localized stage, survival rates are comparable across racial and ethnic groups. 12 Patients and health systems are increasingly using SBTs for convenience and patient preference 13,14 and to maximize population-level screening rates without a substantial increase in costs.…”

Section: Introductionmentioning

confidence: 99%

“…Diagnosis at an early stage will reduce neoplastic progression of disease and therefore increase the possibility of curative treatment . It follows that early diagnosis may also decrease downstream complications, improve outcomes, and minimize costs to the patient and the health care system . Further, early diagnosis helps reduce racial and ethnic disparities in outcomes: when CRC is diagnosed at a localized stage, survival rates are comparable across racial and ethnic groups …”

Section: Introductionmentioning

confidence: 99%

Development of a Follow-Up Measure to Ensure Complete Screening for Colorectal Cancer

Ciemins,

Mohl,

Moreno

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceThe current quality performance measure for colorectal cancer (CRC) screening is limited to initial screening. Despite low rates, there is no measure for appropriate follow-up with colonoscopy after receipt of an abnormal result of a stool-based screening test (SBT) for CRC. A quality performance measure is needed.ObjectiveTo develop and test a quality performance measure for follow-up colonoscopy within 6 months of an abnormal result of an SBT for CRC.Design, Setting, and ParticipantsThis retrospective quality improvement study examined data from January 1, 2016, to December 31, 2020, with 2018 plus 6 months of follow-up as the primary measurement period to verify performance rates, specify a potential measure, and test for validity, reliability, and feasibility. The Optum Labs Data Warehouse (OLDW), a deidentified database of health care claims and clinical data, was accessed. The OLDW contains longitudinal health information on enrollees and patients, representing a diverse mixture of ages and geographic regions across the US. For the database study, adults from 38 health care organizations (HCOs) aged 50 to 75 years who completed an initial CRC SBT with an abnormal result were observed to determine follow-up colonoscopy rates within 6 months. Rates were stratified by race, ethnicity, sex, insurance, and test modality. Three HCOs participated in the feasibility field testing. Data were analyzed from June 1, 2022, to May 31, 2023.Main Outcome and MeasuresThe primary outcome consisted of follow-up colonoscopy rates following an abnormal SBT result for CRC. Reliability statistics were also calculated across HCOs, race, ethnicity, and measurement year.ResultsAmong 20 581 adults (48.6% men and 51.4% women; 307 [1.5%] Asian, 492 [7.2%] Black, 644 [3.1%] Hispanic, and 17 705 [86.0%] White; mean [SD] age, 63.6 [7.1] years) in 38 health systems, 47.9% had a follow-up colonoscopy following an abnormal SBT result for CRC within 6 months. There was significant variation between HCOs. Notably, significantly fewer Black patients (37.1% [95% CI, 34.6%-39.5%]) and patients with Medicare (49.2% [95% CI, 47.7%-50.6%]) or Medicaid (39.2% [95% CI, 36.3%-42.1%]) insurance received a follow-up colonoscopy. A quality performance measure that tracks rates of follow-up within 6 months of an abnormal SBT result was observed to be feasible, valid, and reliable, with a median reliability statistic between HCOs of 94.5% (range, 74.3%-99.7%).Conclusions and RelevanceThe findings of this observational study of 20 581 adults suggest that a measure of follow-up colonoscopy within defined periods after an abnormal result of an SBT test for CRC is warranted based on low current performance rates and would be feasible to collect by health systems and produce valid, reliable results.

show abstract

“…What is the societal cost of missing early‐stage CRC and thus early treatment? The cost of managing metastatic CRC imposes a substantial economic burden on patients, caregivers, populations, and the healthcare system 8 . From a systematic review of studies that included the medical cost of systemic therapy, the cost of treating one metastatic CRC was estimated at US$300 000, a prohibitively high health care expenditure in most countries 8 .…”

mentioning

confidence: 99%

“…The cost of managing metastatic CRC imposes a substantial economic burden on patients, caregivers, populations, and the healthcare system 8 . From a systematic review of studies that included the medical cost of systemic therapy, the cost of treating one metastatic CRC was estimated at US$300 000, a prohibitively high health care expenditure in most countries 8 . This does not even include the costs associated with loss of productivity, job absenteeism, early retirement due to the disease, and various damages of the disease stigma and therapies on one's psychological and social well‐being.…”

mentioning

confidence: 99%

Is the practice of colorectal cancer screening questionable after the NordICC trial was published?

Wong,

Huang,

Liang

2023

Clinical & Translational Med

View full text Add to dashboard Cite

Cost of treating metastatic colorectal cancer: a systematic review

Cited by 15 publications

References 40 publications

Analysis of the composition and influencing factors of hospitalization expenses for 1517 patients with lung malignant tumors in Beijing

Analysis of the composition and influencing factors of hospitalization expenses for 1517 patients with lung malignant tumors in Beijing

Development of a Follow-Up Measure to Ensure Complete Screening for Colorectal Cancer

Is the practice of colorectal cancer screening questionable after the NordICC trial was published?

Contact Info

Product

Resources

About